Try our Advanced Search for more refined results

Biogen To Pay $1.25B For Forward Pharma's MS Drug IP

By Kevin Penton (January 17, 2017, 6:35 PM EST) -- Biogen Inc. on Tuesday agreed to pay $1.25 billion to Forward Pharma A/S so it can license all of the Danish company's intellectual property, as the two companies continue to battle in U.S. and European courts over patents related to multiple sclerosis drugs....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!